Welcome to Arrien Pharmaceuticals
Arrien Pharmaceuticals is a clinical stage drug discovery company focused on developing small molecules targeting protein kinase signaling, nuclear hormone receptor and immuno-oncology/checkpoint pathway targets for treating human cancers, autoimmune and neurodegenerative diseases.
The company successfully applied its proprietary platform "FIELDS" technology and discovered two clinical candidates and others in development:
- ARN-6039 (currently known as BOS-172767), an orally available, selective small molecule inhibitor of ROR-γt (retinoic acid-related orphan nuclear hormone receptor gamma-t) being investigated in a Phase 1 clinical trials. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. ARN-6039 was partnered with Boston Pharmaceuticals in 2017. A Phase 2 clinical POC studies in psoriasis and other autoimmune indications planed for Q3 2019. Our partner Boston Pharmaceuticals advancing several of their compounds in clinical trials that were the outcome of discovery collaborations and the responsibility for developing ARN-6039/BOS-172767 is with our partner.
- ARN-3261, an orally available small molecule inhibitor of SIK2 (Salt Inducible Kinase 2) to be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. An IND being approved to initiate the Phase 1a/1b trials beginning of Q1 2019.
- ARN-0953, an orally available, highly selective small molecule inhibitor of the MELK (Maternal Embryonic Leucine Zipper Kinase) and FLT3/CD135 (FMS like Tyrosine Kinase 3) specific kinases. ARN-0953 currently in IND enabling studies and to be investigated in Phase 1 clinical trials for AML and other solid tumors (TNBC, GBM & Lung cancers) in Q4 2019.
- ARN-0894, an orally available, small molecule agonist of stimulatory checkpoint pathway targets responsible for costimulatory signals. Several agonist mAbs have been developed to engage with these checkpoint pathway targets and ARN-0894 currently in pre-clinicals stage of development. ARN-0894 discovered to potentially enhance the anti-tumor immunity though co-stimulatory mechanism. IND enabling studies to follow the initiation of Phase 1 clinical trials in Q3 2020.
Arrien Pharmaceuticals competitive and unique drug discovery and development approaches coupled with experienced scientific, clinical and business team who are expertise in multidisciplinary areas of kinase signaling, nuclear hormone receptor and checkpoint pathways and technology has been the key to company's success since its incorporation in 2011.